F.D.A. Approves Lecanemab as New Treatment for Early Alzheimer’s

Food and Drug Administration on January 7, 2023, approved another Alzheimer’s drug that may modestly slow the pace of cognitive decline early in the disease, but also carries risks of swelling and bleeding in the brain.